- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06525298
EIS-12656 como agente único y en combinación en pacientes con tumores sólidos específicos
A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor, Trastuzumab Deruxtecan (T-DXd), or Darolutamide in Patients With Specified Solid Tumors
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The trial is a Phase 1/2, open label, uncontrolled trial to investigate the safety and preliminary efficacy of EIS-12656 alone or in combination with a PARPi, T-DXd or darolutamide in patients with specified advanced or metastatic solid tumors with homologous recombination deficient (HRD) mutations.
In the Phase 1 dose escalation phase participants will receive ascending doses of EIS-12656 to evaluate the safety and tolerability and to determine an effective and safe dose for the Phase 2 part.
In the Phase 2 dose expansion phase participants will either receive EIS-12656 monotherapy at the recommended Phase 2 dose (RP2D) (Module 1) or EIS-12656 in combination with a PARPi (Module 2), or T-DXd (Modules 3), or darolutamide (Module 4). The objective is to evaluate the safety and tolerability and anti-tumor activity of EIS-12656 alone or in combination.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Adrian Schomburg
- Número de teléfono: +49 17621046886
- Correo electrónico: adrian@eisbach.bio
Ubicaciones de estudio
-
-
Louisiana
-
Shreveport, Louisiana, Estados Unidos, 71103
- Reclutamiento
- LSU Health Sciences Center- Shreveport
-
Investigador principal:
- Sindhu Devarashetty, MD
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Reclutamiento
- Duke Cancer Institute
-
Investigador principal:
- Rani Bansal, MD
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- MD Anderson Cancer Center
-
Investigador principal:
- Timothy Yap, MD
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- Fred Hutchinson Cancer Center
-
Investigador principal:
- Jennifer Specht, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Recurrent locally advanced or metastatic solid tumors
- Homologous recombination deficient mutations
- Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy
- Measurable disease (RECIST 1.1 Criteria)
- Adequate organ and bone marrow function
- ECOG Performance Status 0 or 1
- Life expectancy > 3 months
Exclusion Criteria:
- History or evidence of any clinically relevant gastrointestinal disease
- Radiation therapy within ≤2 weeks
- Significant cardiovascular disease
- Uncontrolled, active, symptomatic brain metastases
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: EIS-12656 Aumento de dosis
|
EIS-12656 tablets given daily |
|
Experimental: Módulo de expansión de dosis 1 (monoterapia EIS-12656)
|
EIS-12656 tablets given daily |
|
Experimental: Dose Expansion Module 2 (EIS-12656 + PARPi)
EIS-12656 will be given in combination with PARPi |
EIS-12656 tablets given daily as per USPI/SmPC |
|
Experimental: Dose Expansion Module 3 (EIS-12656 + T-DXd)
EIS-12656 will be given in combination with Trastuzumab deruxtecan |
EIS-12656 tablets given daily as per USPI/SmPC
Otros nombres:
|
|
Experimental: Dose Expansion Module 4 (EIS-12656 + darolutamide + ADT)
EIS-12656 will be given in combination with darolutamide and androgen deprivation therapy (ADT) |
EIS-12656 tablets given daily as per USPI/SmPC |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number and percentage of participants experiencing treatment-emergent adverse events (TEAEs)
Periodo de tiempo: From screening until end of treatment follow-up (45 days after last dose) (up to 7 months)
|
Number and percentage of participants with adverse events, serious adverse events, adverse events of special interest including changes in safety lab parameters, physical examinations, vital signs, and electrocardiogram (ECG) |
From screening until end of treatment follow-up (45 days after last dose) (up to 7 months)
|
|
Number and percentage of participants experiencing a dose limiting toxicity (DLT) (dose escalation part only)
Periodo de tiempo: Within 21 days of first dose
|
A DLT is defined as an EIS-12656 related adverse event during the first treatment cycle that meets the criteria outlined in the study protocol |
Within 21 days of first dose
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximum plasma concentration of EIS-12656 (Cmax)
Periodo de tiempo: At pre-defined intervals from pre-dose Day 1 to Day 29
|
The concentration of EIS-12656 in plasma will be determined (Cmax will be derived) |
At pre-defined intervals from pre-dose Day 1 to Day 29
|
|
Area under the curve (AUC0-24)
Periodo de tiempo: At pre-defined intervals from pre-dose Day 1 to Day 29
|
The AUC0-24 reflects the actual body exposure to drug over the last 24h dosing interval |
At pre-defined intervals from pre-dose Day 1 to Day 29
|
|
Time to maximum concentration (Tmax)
Periodo de tiempo: At pre-defined intervals from pre-dose Day 1 to Day 29
|
The concentration of EIS-12656 in plasma will be determined (Tmax will be derived) |
At pre-defined intervals from pre-dose Day 1 to Day 29
|
|
Overall Response Rate
Periodo de tiempo: From screening to disease progression (approximately 1 year)
|
Overall response rate defined as percentage of participants with the best overall response of confirmed CR or confirmed PR according to RECIST v1.1 |
From screening to disease progression (approximately 1 year)
|
|
Duration of Response
Periodo de tiempo: From screening to disease progression or death (approximately 1 year)
|
Time from first response to progression or death, as defined by RECIST 1.1 |
From screening to disease progression or death (approximately 1 year)
|
|
Progression Free Survival
Periodo de tiempo: From screening to disease progression or death (approximately 1 year)
|
Time from first dose of EIS-12656 to progression or death, as defined by RECIST 1.1 |
From screening to disease progression or death (approximately 1 year)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- EIS-12656C01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .